RO-28-1675 (C007B-416217)

RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC 50 of 54 nM. RO-28-1675 can be used for the research of type 2 diabetesIn VitroRO-28-1675 can reverse the inhibitory action of the human glucokinase regulatory protein (GKRP). MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoRO-28-1675 (50 mg/kg; p.o.) reduces blood glucose levels in wild-type C57BL/6J mice. RO-28-1675 exhibits high oral bioavailability (mice 92.8%) and C max (1140 μg/mL) following oral administration (10 mg/kg) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 10 weeks old male C57BL/6J miceDosage: 50 mg/kg Administration: Oral administration Result: Reduced blood glucose levels. Animal Model: C57BL/6J mice Dosage: 10 mg/kg (Pharmacokinetic Analysis Administration: Oral administration Result: Oral bioavailability (92.8%), C max (1140 μg/mL), T max (3.3 h).IC50& Target:EC50: 54 nM (glucokinase).

Specifications and Purity: 10mM in DMSO

Molecular Formula: C18H22N2O3S2

Molecular Weight: 378.51